Background. Previous studies suggest that RSV increases NP bacterial colonization and may facilitate infection. However, the role of NP colonization with potentially pathogenic bacteria (PPB) in the pathogenesis of RSV bronchiolitis is not well understood. We sought to determine the frequency, type, and density of NP PPB detection in infants with RSV infection compared with healthy controls (HC), and its association with clinical outcomes.
Background. The World Health Organization (WHO) has identified the need for a nonsputum-based triage test for tuberculosis (TB) that can be used to identify those who need further testing to identify active disease. We investigated whether our previously described 3-gene TB score could identify individuals with active tuberculosis (ATB) prior to seeking care ("active case detection") and how the 3-gene TB score correlated with the timing of disease onset, disease severity, and response to treatment.
Methods. This study consisted of a prospective nested case-control trial, Brazil Active Screening Study (BASS; 2016) , and re-analysis of data from 2 prospective cohort studies, the Adolescent Cohort Study (ACS; 2005 -2007 , and the Catalysis Treatment Response Cohort (CTRC; 2010 -2013 . The BASS case-control subcohort contained 81 adults (ages 20-72 years, 33 ATB, 48 controls). The ACS contained 153 adolescents (ages 12-18 years, 46 ATB, 107 LTBI). The CTRC-contained 138 adults (ages 17-67 years, 100 ATB, 17 other lung disease patients, 21 healthy controls).
Results. The 3-gene TB score diagnosed ATB patients with high accuracy: BASS cohort AUC = 0.87 (95% CI = 0.82-0.91, Figure 1A ), ACS cohort AUC = 0.86 (95% CI = 0.76-0.97, Figure 1B) , and CTRC AUC = 0.93 (95% CI = 0.88-0.97). In the ACS, the 3-gene TB score predicted progression from LTBI to ATB 6 months prior to positive sputum test (AUC = 0.86; 95% CI = 0.79-0.92, Figure 1B ). In the CTRC, the 3-gene TB score correlated with glycolytic activity ratio of PET-CT at baseline (correlation = 0.54, P = 3.98 × 10 −8 , Figure 1C ) and at the end of treatment (correlation = −0.408, P = 3.72 × 10 −5
). In the CTRC, the 3-gene TB score at baseline predicted the likelihood of prolonged sputum positivity following treatment initiation and treatment response at 6 months (P = 3.6 × 10 −5
). Collectively, across all cohorts, the 3-gene TB score identified ATB patients with 90% sensitivity and 70% specificity, and had 99% negative predictive value (NPV) at 5% prevalence.
Conclusion. Across 3 independent prospective cohorts, the 3-gene TB score closely approaches the WHO target product profile benchmarks for non-sputumbased triage test at high NPV. These performance characteristics make it a potential test for ruling out ATB and for monitoring disease status. 
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